Skip to main content

Table 1 Demographics and clinical characteristics of patients treated with ONC201 who were evaluable for safety and efficacy

From: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

  Patients (N = 20)
ONC201 (mg) 375 625
No. of Patients (%) 3 (15%) 17 (85%)
Male 2 8
Female 1 9
ECOG
 ECOG = 0 2 (10%) 6 (30%)
 ECOG = 1 1 (5%) 11 (55%)
Age (years)a 80 (42–92) 64 (35–79)
Weight (kg)a 51.3 (50.4–55.0) 82.7 (56.4–109.1)
Dosesa 21 (18–30) 19.6 (4–70)
Prior Therapies
 Prior hormonal therapiesa 0 1.2 (1–6)
 Prior chemotherapiesa 2.3 (0–4) 2.2 (0–7)
 Prior immunotherapiesa 1 (0–2) 0.2 (0–1)
 Prior targeted therapiesa 0.7 (0–2) 0.8 (0–4)
Prior Radiationa 1.5 (1–2) 1 (1–3)
Prior Surgerya 2 (2–3) 3 (1–7)
  1. a Indicates that the datum is reported as the mean with the range in parentheses